Outlook Therapeutics (OTLK) Short Interest Ratio & Short Volume → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free OTLK Stock Alerts $7.43 +0.03 (+0.41%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Outlook Therapeutics Short Interest DataCurrent Short Volume1,260,000 sharesPrevious Short Volume1,130,000 sharesChange Vs. Previous Month+11.50%Dollar Volume Sold Short$11.24 millionShort Interest Ratio / Days to Cover2.0Last Record DateApril 30, 2024Outstanding Shares13,010,000 sharesFloat Size16,470,000 sharesShort Percent of Float7.65%Today's Trading Volume225,179 sharesAverage Trading Volume488,157 sharesToday's Volume Vs. Average46% Short Selling Outlook Therapeutics ? Sign up to receive the latest short interest report for Outlook Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatOTLK Short Interest Over TimeOTLK Days to Cover Over TimeOTLK Percentage of Float Shorted Over Time Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company Outlook Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,260,000 shares $11.24 million +11.5%7.7%2 $8.92 4/15/20241,130,000 shares $9.74 million -15.0%7.4%1.8 $8.62 3/31/20241,330,000 shares $15.88 million +69.4%6.2%2.2 $11.94 3/15/2024785,300 shares $6.47 million -93.3%10.6%1.6 $8.24 2/29/202411,640,000 shares $5.08 million -11.8%7.9%6 $0.44 2/15/202413,200,000 shares $6.40 million -2.7%9.0%6.5 $0.48 Get the Latest News and Ratings for OTLK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202413,570,000 shares $5.24 million +11.9%9.2%5.9 $0.39 1/15/202412,130,000 shares $4.47 million +7.3%9.2%1.9 $0.37 12/31/202311,310,000 shares $4.46 million +3.3%8.6%1.6 $0.39 12/15/202310,950,000 shares $4.20 million -32.1%8.3%1.5 $0.38 11/30/202316,130,000 shares $7.74 million -21.5%12.2%2.1 $0.48 11/15/202320,540,000 shares $9.16 million -35.9%16.0%1.8 $0.45 10/31/202332,030,000 shares $19.22 million +9.4%25.0%2.8 $0.60 10/15/202329,270,000 shares $9.51 million +9.5%22.9%3.2 $0.33 9/30/202326,720,000 shares $5.91 million +3.4%20.9%4.5 $0.22 9/15/202325,850,000 shares $5.56 million -3.0%20.2%4.6 $0.22 8/31/202326,660,000 shares $6.08 million +52.3%21.1%5.2 $0.23 8/15/202317,510,000 shares $27.14 million +4.9%13.9%12.2 $1.55 7/31/202316,700,000 shares $28.89 million +1.8%13.4%13.1 $1.73 7/15/202316,410,000 shares $27.08 million -2.2%13.2%13.2 $1.65 6/30/202316,770,000 shares $29.18 million -1.9%13.5%15.2 $1.74 6/15/202317,100,000 shares $30.44 million +3.9%13.7%16.6 $1.78 5/31/202316,460,000 shares $24.69 million +0.6%13.2%19.1 $1.50 5/15/202316,370,000 shares $19.64 million -3.1%13.1%24.5 $1.20 4/30/202316,890,000 shares $17.73 million +0.6%13.6%28.6 $1.05 4/15/202316,790,000 shares $18.13 million +2.2%13.6%29.7 $1.08 3/31/202316,430,000 shares $17.91 million +6.1%13.3%27.6 $1.09 3/15/202315,490,000 shares $15.64 million +2.9%12.5%24.9 $1.01 2/28/202315,050,000 shares $16.40 million -1.4%12.2%27.1 $1.09 2/15/202315,270,000 shares $17.71 million -2.9%12.4%29 $1.16 1/31/202315,730,000 shares $18.09 million +3.8%11.7%32 $1.15 1/15/202315,150,000 shares $20.45 million -5.4%12.7%30.2 $1.35 12/30/202216,020,000 shares $17.30 million +0.4%33.0%36.9 $1.08 12/15/202215,960,000 shares $14.37 million -1.1%12.1%34.6 $0.90 11/30/202216,130,000 shares $16.78 million -1.7%12.2%35.1 $1.04 11/15/202216,400,000 shares $17.38 million +3.0%12.4%34.7 $1.06 10/31/202215,930,000 shares $18.48 million +3.6%12.0%33.8 $1.16 10/15/202215,380,000 shares $18.46 million +6.7%11.6%33.4 $1.20 9/30/202214,420,000 shares $17.59 million +5.6%10.9%30.8 $1.22 9/15/202213,660,000 shares $15.71 million +9.2%10.3%29.1 $1.15Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. OTLK Short Interest - Frequently Asked Questions What is Outlook Therapeutics' current short interest? Short interest is the volume of Outlook Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 1,260,000 shares of OTLK short. 7.65% of Outlook Therapeutics' shares are currently sold short. Learn More on Outlook Therapeutics' current short interest. What is a good short interest ratio for Outlook Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OTLK shares currently have a short interest ratio of 2.0. Learn More on Outlook Therapeutics's short interest ratio. What is a good short interest percentage for Outlook Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.65% of Outlook Therapeutics' floating shares are currently sold short. Is Outlook Therapeutics' short interest increasing or decreasing? Outlook Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,260,000 shares, an increase of 11.5% from the previous total of 1,130,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Outlook Therapeutics' float size? Outlook Therapeutics currently has issued a total of 13,010,000 shares. Some of Outlook Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Outlook Therapeutics currently has a public float of 16,470,000 shares. How does Outlook Therapeutics' short interest compare to its competitors? 7.65% of Outlook Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Outlook Therapeutics: Curis, Inc. (1.14%), Passage Bio, Inc. (4.28%), AlloVir, Inc. (5.85%), Athira Pharma, Inc. (2.97%), Gritstone bio, Inc. (15.43%), DBV Technologies S.A. (0.28%), Elutia Inc. (0.20%), Precision BioSciences, Inc. (9.31%), Cognition Therapeutics, Inc. (0.56%), bluebird bio, Inc. (29.14%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Outlook Therapeutics stock? Short selling OTLK is an investing strategy that aims to generate trading profit from Outlook Therapeutics as its price is falling. OTLK shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Outlook Therapeutics? A short squeeze for Outlook Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLK, which in turn drives the price of the stock up even further. How often is Outlook Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLK, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Curis Short Interest Data Passage Bio Short Interest Data AlloVir Short Interest Data Athira Pharma Short Interest Data Gritstone bio Short Interest Data DBV Technologies Short Interest Data Elutia Short Interest Data Precision BioSciences Short Interest Data Cognition Therapeutics Short Interest Data bluebird bio Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OTLK) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange